Although the initial indications for PPAR agonist treatment mainly focus on hyperlipidemia and diabetes, there is a growing body of data which suggest that they maybe improve cardiac function with decreased fibrosis, improved contractility, and endothelial function in animal models of systolic HF [66]. The gene discussed is PPARA; the disease is diabetes mellitus.